- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04731025
Local Antibiotics for Breast Implants (BREAST-AB)
May 9, 2024 updated by: Mikkel Herly
Prophylactic Treatment of Breast Implants With a Solution of Gentamicin, Vancomycin and Cefazolin Antibiotics for Women Undergoing Breast Reconstructive Surgery: a Randomized Controlled Trial (The BREAST-AB Trial)
The BREAST-AB Trial is a multi-center, randomized, double blind, placebo-controlled trial investigating the efficacy of local application of gentamicin, vancomycin and cefazolin in decreasing all-cause implant explantation after breast reconstruction.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The BREAST-AB Trial will include women undergoing breast reconstruction with implants.
The objective is to determine the efficacy of local antibiotics in decreasing all-cause implant explantation.
Participants will be randomized to local application of placebo or gentamicin, vancomycin and cefazolin in a saline solution onto the implant and the dissected breast pocket.
All patients undergoing unilateral breast reconstruction will be randomized to the trial drug or placebo in a ratio of 1:1.
All patients undergoing bilateral reconstruction will be randomized to the trial treatment on one of their breasts and placebo to the contralateral breast.
A total number of 1274 of breasts undergoing breast reconstruction will be included in the trial.
Study Type
Interventional
Enrollment (Estimated)
1003
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mikkel Herly, MD, Ph.D.
- Phone Number: +45 27598919
- Email: mikkel.herly@regionh.dk
Study Contact Backup
- Name: Mathilde Hemmingsen, MD
- Phone Number: +45 28568205
- Email: mathilde.nejrup.hemmingsen@regionh.dk
Study Locations
-
-
-
Aalborg, Denmark, 9000
- Recruiting
- Aalborg University Hospital
-
Contact:
- Lene Birk-Sørensen, MD
- Phone Number: +45 97660624
- Email: l.birksoerensen@rn.dk
-
Aarhus, Denmark, 8000
- Recruiting
- Aarhus University Hospital
-
Contact:
- Mikkel Rindom, MD
- Phone Number: +45 24 60 93 21
- Email: MIKKOC@rm.dk
-
Copenhagen, Denmark, 2100
- Recruiting
- Rigshospitalet
-
Contact:
- Mikkel Herly, MD, Phd
- Phone Number: +45 27598919
- Email: mikkel.herly@regionh.dk
-
Contact:
- Mathilde N Hemmingsen, MD
- Phone Number: +45 28568205
- Email: mathilde.nejrup.hemmingsen@regionh.dk
-
Esbjerg, Denmark, 6700
- Not yet recruiting
- South-West Jutland Hospital
-
Contact:
- Lena F Carstensen, MD
- Phone Number: +45 20 15 20 19
- Email: Lena.Felicia.Carstensen@rsyd.dk
-
Herlev, Denmark, 2730
- Recruiting
- Herlev and Gentofte Hospital
-
Contact:
- Lisbet R Hölmich, MD, DMSc
- Phone Number: +45 27 20 00 14
- Email: lisbet.rosenkrantz.hoelmich@regionh.dk
-
Odense, Denmark, 5000
- Recruiting
- Odense University Hospital
-
Contact:
- Camilla Bille, Phd
- Phone Number: +45 65 41 24 45
- Email: Camilla.Bille@rsyd.dk
-
Roskilde, Denmark, 4000
- Recruiting
- Zealand University Hospital
-
Contact:
- Michael Rose, MD
- Email: mrose@regionsjaelland.dk
-
Vejle, Denmark, 7100
- Not yet recruiting
- Vejle Hospital
-
Contact:
- Bekka Christensen, MD
- Email: Bekka.Anina.Ozer.Christensen@rsyd.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age ≥ 18 years
- Biologically female
- Signed informed consent
Scheduled for breast reconstruction with implants or expanders including:
- Immediate or delayed reconstructions
- Bilateral or unilateral reconstructions
- With or without simultaneous flap reconstruction
Exclusion Criteria:
- Pregnancy
- Breast feeding
- Known allergy towards Vancomycin, Gentamicin and Cefazolin
- Known anaphylactic reaction towards other beta-lactam antibiotics or aminoglycosides
- Known allergy towards neomycin
- Known impaired renal function with GFR < 60 mL/min
- Participation in investigational drug trials and projects concerning disinfecting agents in the breast implant cavity
- Myasthenia Gravis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Irrigation of implants with sterile isotonic saline
The placebo solution will consist of 500 mL of sterile isotonic (9%) saline contained in a infusion bag.
|
500 mL of sterile isotonic (9%) saline.
The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
Other Names:
|
Experimental: Irrigation of implants with a triple antibiotic solution
The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in 500 mL sterile isotonic (9%) saline
|
The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in a 500 mL isotonic saline solution.
The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause explantation of the breast implant after the breast reconstruction surgery
Time Frame: 180 days
|
All-cause explantation will be defined as explantation and discarding of the implant.
Replacement of an expander with a permanent implant and replacement of a permanent breast implant with a new permanent breast implant due to cosmetic revisions such as asymmetry, implant malposition, change of size or implant rotation will not be counted as an explantation.
|
180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to explantation (days)
Time Frame: 180 days
|
Time to explantation will be defined as the amount of days between the breast reconstruction and the implant explantation surgery.
|
180 days
|
Revision surgery with incision of the fibrous capsule after the breast reconstruction surgery (Y/N)
Time Frame: 180 days
|
The breast reconstruction surgery will be defined as the surgery where they received the allocated treatment
|
180 days
|
Exchange of permanent implant to expander implant after the breast reconstruction surgery (Y/N)
Time Frame: 180 days
|
The breast reconstruction surgery will be defined as the surgery where they received the allocated treatment
|
180 days
|
Surgical site infection that leads to antibiotic treatment after the breast reconstruction surgery
Time Frame: 180 days
|
Surgical site infection will be defined according to the CDC classification of surgical site infetion leading to antibiotic treatment with oral or intravenous antibiotics administered after the surgery.
|
180 days
|
All-cause explantation of the breast implant within 1 year after the breast reconstruction surgery
Time Frame: 1 year
|
All-cause explantation will be defined as explantation and discarding of the implant.
Replacement of an expander with a permanent implant and replacement of a permanent breast implant with a new permanent breast implant due to cosmetic revisions such as asymmetry, implant malposition, change of size or implant rotation will not be counted as an explantation.
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time from the breast reconstruction surgery to discharge (days)
Time Frame: 180 days
|
Time to discharge will be defined as the amount of days between the breast reconstruction and the day of discharge.
|
180 days
|
Re-admission after the breast reconstruction surgery (Y/N)
Time Frame: 180 days
|
The breast reconstruction surgery will be defined as the surgery where the patient received the allocated treatment.
|
180 days
|
Long term follow-up after 5, 10 and 15 years
Time Frame: 15 years
|
Capsular contracture and the Baker classification grade will be obtained from the National Patient Registry and the patients' medical journals after 5, 10 and 15 years.
The BREAST-Q questionnaire will be used to assess patient-reported outcomes.
The patients will be contacted and asked to fill out the questionnaire with 5 year-intervals after the surgery.
|
15 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mikkel Herly, MD, Ph.D., Department of Plastic Surgery and Burns Treatment
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 27, 2021
Primary Completion (Estimated)
July 27, 2025
Study Completion (Estimated)
January 27, 2026
Study Registration Dates
First Submitted
January 26, 2021
First Submitted That Met QC Criteria
January 26, 2021
First Posted (Actual)
January 29, 2021
Study Record Updates
Last Update Posted (Estimated)
May 10, 2024
Last Update Submitted That Met QC Criteria
May 9, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Inflammation
- Postoperative Complications
- Disease Attributes
- Joint Diseases
- Musculoskeletal Diseases
- Muscular Diseases
- Foreign-Body Reaction
- Prosthesis Failure
- Infections
- Communicable Diseases
- Contracture
- Implant Capsular Contracture
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Vancomycin
- Gentamicins
- Cefazolin
Other Study ID Numbers
- BREAST-AB-01
- 2020-002459-40 (EudraCT Number)
- 0058322 (Other Grant/Funding Number: Novo Nordisk Foundation)
- R-189- A4127 (Other Grant/Funding Number: Medicine Fund of the Danish Regions)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The protocol including the statistical analysis plan is published in BMJ Open (doi:10.1136/bmjopen-2021-058697)
prior to unblinding.
The main article will include the primary and secondary outcomes.
The tertiary and long-term outcomes will be included in subsequent articles.
The manuscripts will be submitted to peer-reviewed international journals and both positive, negative and inconclusive results will be published.
The findings of the trial will be shared with participating sites and presented at national and international conferences.
The results will be disseminated to the public but will not be shared directly with participating patients.
IPD Sharing Time Frame
After the end of the trial, the data will become available (Anticipated july 2025)
IPD Sharing Access Criteria
Researchers and other relevant parties can be granted access to selected anonymized data after publication upon request to the principal-sponsor investigator
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibiotic Side Effect
-
H. Tolga ÇelikCompletedAntibiotic Side EffectTurkey
-
Milton S. Hershey Medical CenterCompleted
-
Cultech LtdComac MedicalCompleted
-
Tel-Aviv Sourasky Medical CenterWeizmann Institute of ScienceUnknownAntibiotic Side Effect | Gut MicrobiomeIsrael
-
Intermountain Health Care, Inc.Centers for Disease Control and PreventionRecruitingAntibiotic Side Effect | Behavioral ChangesUnited States
-
Cairo UniversityNot yet recruitingAntibiotic Side Effect | Antibiotic Resistant Infection
-
University Hospital, SaarlandBayerCompletedSide-effect of AntibioticGermany
-
Wecare Probiotics Co., Ltd.MethodexCompletedDiarrhea | Probiotics | Antibiotic Side EffectSpain
-
Seed HealthCompletedMetagenomic and Metabolomic Reconstitution of Gut Microbiota After Broad Spectrum Antibiotic TherapyAntibiotic-associated Diarrhea | Antibiotic Side Effect | Antibiotic-induced Dysbiosis | Antibiotic-induced Epithelial Barrier DisintegrityCanada
-
Universiti Sains MalaysiaNot yet recruitingAntibiotic Side Effect
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States